Project Grant R21AI190593
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $233K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $272,125 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the essential transcription factors of Cryptococcus neoformans. The research identifies and characterizes twelve transcription factors in C. neoformans that previous systematic deletion efforts failed to produce, provisionally classified as essential transcription factors. The project...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $482,071 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on copper homeostasis in fungal pathogenesis. The research uses Cryptococcus neoformans as a model system to explore how copper availability influences fungal survival during infection. The work examines cellular adaptations as this opportunistic pathogen transitions between high copper...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $263,895 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the pathophysiology of invasive fungal sinusitis, a severe fungal infection affecting immunocompromised patients. The research will examine the mechanisms of fungal invasion and mucosal barrier degradation in invasive fungal sinusitis, with focus on fungal virulence, matrix metalloproteinase...
- The National Institute of Allergy and Infectious Diseases awarded $427,626 to The Washington University on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify host factors that mediate nuclear retention of unspliced and partially spliced HIV-1 transcripts. The project will determine mechanisms by which intron-containing HIV-1 RNA molecules remain in the nucleus, contrasting with fully spliced viral messenger RNA that readily accesses host nuclear...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $242,250 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate a novel mycovirus and its impacts on the biology and pathogenesis of Cryptococcus neoformans. The research characterizes a recently discovered double-stranded RNA totivirus (CNTV1) identified in C. neoformans RNAi-deficient clinical isolates. The investigation defines the molecular and functional impact...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, College Park $1,498,706 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the cellular and molecular mechanisms of cryptococcal immune reconstitution inflammatory syndrome (IRIS). The recipient will use a novel murine model of Cryptococcus neoformans infection to identify the leukocyte subsets and cytokines mediating lethal cryptococcal IRIS, and to...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine a Project Grant totaling $1,486,296 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the human antibody response to Cryptococcus neoformans and survival outcomes in HIV-associated cryptococcal meningoencephalitis, a devastating opportunistic infection of the central nervous system that occurs predominantly in people...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $427,623 to The Washington University on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research dissecting how HIV-induced immunometabolic perturbation impairs tuberculosis control in people living with HIV despite effective antiretroviral therapy and viral suppression. The research...
- The National Institute of Allergy and Infectious Diseases awarded Washington University $466,500 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate aberrant wound healing responses that drive myeloid-dependent disease exacerbation in mycobacterium tuberculosis infection. The research leverages existing single-cell RNA-sequencing datasets and generates new spatial transcriptomic profiling of human and mouse MTB-infected lungs to identify...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $791,065 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into the role of capsid interactions with viral RNA genome in assembly of HIV-1 cores. The research investigates how HIV-1 capsid proteins and viral RNA genome components organize during viral maturation. The study will clarify structural mechanisms underlying HIV-1 core formation,...